CARE Consortium Biobank
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
May 01, 2025 - April 30, 2026
Grant ID
CA2025003
Goals
The project purpose is to characterize genomic factors that increase the risk of developing Alzheimer’s & Related Dementias (ADRD) in individuals exposed to concussion and repetitive head impacts.
Unique and Innovative
This proposal applies emerging understanding of the genomic factors of ADRD to a large cohort of young adults with varying degrees of exposure to concussion/mTBI and repetitive head impacts. This cohort of males and females has been characterized with brain health measures and followed in a prospective longitudinal design for 10 years. This study will elucidate the interaction between neurotrauma and genetic risk profile for ADRD. It offers the potential to identify individuals showing very early pre-clinical features of ADRD, who might benefit from emerging disease modifying therapies.
Foreseeable Benefits
This study addresses public health concerns about whether exposure to repetitive head impacts and /or concussion as a young adult increases the risk of developing ADRD, and if genomic factors associated with ADRD amplify this risk. It will inform our understanding of the interaction of genetic and environmental risk factors for ADRD and offer the potential for very early identification of those individuals at greatest risk for ADRD, who might benefit from disease modifying therapies
Related Grants
Alzheimer's Disease Research
Expanding and Enhancing LASI-DAD for Better Understanding of Alzheimer's Disease and Dementia
Active Dates
April 01, 2023 - March 31, 2025
Principal Investigator
Jinkook Lee, PhD
Current Organization
University of Southern California
Expanding and Enhancing LASI-DAD for Better Understanding of Alzheimer's Disease and Dementia
Active Dates
April 01, 2023 - March 31, 2025
Principal Investigator
Jinkook Lee, PhD
Current Organization
University of Southern California
Alzheimer's Disease Research
International Society for Molecular Neurodegeneration
Active Dates
March 31, 2021 - March 30, 2026
Principal Investigator
Henrietta Nielsen, PhD
Current Organization
Stockholm University
International Society for Molecular Neurodegeneration
Active Dates
March 31, 2021 - March 30, 2026
Principal Investigator
Henrietta Nielsen, PhD
Current Organization
Stockholm University
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Current Organization
Astrocyte Pharmaceuticals
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Current Organization
Astrocyte Pharmaceuticals